Marinomed develops products on the basis of its technology platforms. Once they are approved for the market, the products are manufactured and sold by partners via licenses. The relevant segment of the pharmaceutical market – coughs, colds and allergies – is the second-largest category of OTC medicines. Experts project continued growth of around 5% per annum in this segment in the years ahead (Source: OTC YearBook 2018, Nicholas Hall & Companies).
Marinomed is ideally positioned thanks to its innovative, patent protected product portfolio and highly specialized sales partners. Accessing markets in other countries and forging new partnerships will create a whole host of growth opportunities. Additional products based on Carragelose® are in the development stage. This will ensure that Marinomed continues to supply the market for cold medicines with innovative products in future.
Once they have been approved, the Marinosolv® technology platform and the products derived from it will also be marketed via partners. The universality of these platforms allows Marinomed to provide the technology itself under technology licenses, as well as the various products. This will also become a key source of income going forward.